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Developing the host for Targeted Integration cell line development
Michelle Zhou, Isla Cheung, Shirley Yip, Mike Laird, John Joly, Brad Snedecor,
Amy Shen, and Yongping Crawford
Unlike the conventional random integration (RI) cell line development (CLD), the
targeted integration (TI) CLD introduces the transgene at a predetermined “hotspot” in the CHO genome with a defined copy number (1-2 copies). Given the
low copy number and the pretested integration site, TI cell lines likely exhibit
better stability compared to RI cell lines. In this study, we performed a genome
wide screening using transposon based cassette integration and established a TI
host (255-3) that has a single landing cassette inserted in its genome. Host 2553 was able to support the CLD for three test molecules with product titers similar
to those of the corresponding RI cell lines. For two regular antibody test cases,
the top four TI cell lines achieved ~4-5g/L. For a proven difficult to express
antibody, the top four TI lines achieved ~1-1.2g/L. The product titer for this hard
to express molecule was increased 3-fold with additional vector
improvement. Moreover, the timeline for CLD was shortened by ~2 weeks and
resources required per cell line were substantially reduced using the TI
method. Together these data indicate that the TI host we developed can be a
suitable host to support our clinical / commercial CLD.

